NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $12.26 +0.01 (+0.11%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$12.30 +0.04 (+0.30%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dr. Reddy's Laboratories Stock (NYSE:RDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RDY alerts:Sign Up Key Stats Today's Range$12.08▼$12.3150-Day Range$11.54▼$12.8552-Week Range$11.36▼$15.67Volume3.63 million shsAverage Volume3.04 million shsMarket Capitalization$10.24 billionP/E Ratio27.87Dividend Yield0.49%Price Target$1,450.00Consensus RatingHold Company Overview Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible. Its business includes generic pharmaceuticals, branded generics, over-the-counter products, active pharmaceutical ingredients and biosimilars. Dr. Reddy’s portfolio spans therapeutic areas such as gastrointestinal, cardiovascular, diabetes, oncology, pain management, dermatology and central nervous system treatments. The company also provides pharmaceutical development and manufacturing services. Dr. Reddy’s serves patients and healthcare providers in India, North America, Europe and other international markets, including countries in emerging markets. The company is led by Co-Chairman and Managing Director G. V. Prasad and Chief Executive Officer Erez Israeli.AI Generated. May Contain Errors. Read More Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 77% of companies evaluated by MarketBeat, and ranked 124th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialDr. Reddy's Laboratories has a consensus price target of $1,450.00, representing about 11,724.2% upside from its current price of $12.26.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 2 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth26.67% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 26.67% in the coming year, from $0.45 to $0.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 27.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 27.87, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.00.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.54% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.01.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 21.18%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 13.64%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.53% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. News and Social Media2.1 / 5News Sentiment0.42 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by Institutions3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDY Stock News HeadlinesComparing Vireo Growth (OTCMKTS:VREOD) & Dr. Reddy's Laboratories (NYSE:RDY)October 4 at 4:44 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Zentek (OtherZTEKF) and Dr Reddy’s Laboratories (RDY)October 2 at 12:40 PM | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 5 at 1:00 AM | Base Camp Trading (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 24, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 22, 2026 | globenewswire.comTakeda, Dr Reddy's to launch dengue vaccine QDENGA in India by 2027September 18, 2026 | msn.comIndia's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in IndiaSeptember 17, 2026 | reuters.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYSeptember 17, 2026 | prnewswire.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $14.03 at the beginning of the year. Since then, RDY stock has decreased by 12.6% and is now trading at $12.2630. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Ltd (NYSE:RDY) announced its quarterly earnings data on Thursday, July, 23rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.03. The business earned $850.26 million during the quarter, compared to the consensus estimate of $850.56 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 9.49% and a net margin of 10.15%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories's stock split on the morning of Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly minted shares were issued to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/23/2026Today10/05/2026Next Earnings (Estimated)10/23/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RDY's financial health is in the Red zone, according to TradeSmith. RDY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,527Year Founded1984Price Target and Rating Average Price Target for Dr. Reddy's Laboratories$1,450.00 High Price Target$1,450.00 Low Price Target$1,450.00 Potential Upside/Downside+11,724.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.44 Trailing P/E Ratio27.87 Forward P/E Ratio27.25 P/E Growth2.55Net Income$456 million Net Margins10.15% Pretax Margin11.58% Return on Equity9.49% Return on Assets6.32% Debt Debt-to-Equity Ratio0.03 Current Ratio1.90 Quick Ratio1.39 Sales & Book Value Annual Sales$3.58 billion Price / Sales2.86 Cash Flow$0.85 per share Price / Cash Flow14.46 Book Value$4.86 per share Price / Book2.52Miscellaneous Outstanding Shares834,670,000Free Float817,978,000Market Cap$10.24 billion OptionableOptionable Beta0.29 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:RDY) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
